Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.

Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA.

Lung Cancer. 2010 Mar;67(3):311-7. doi: 10.1016/j.lungcan.2009.04.015. Epub 2009 May 30.

PMID:
19482372
[PubMed - indexed for MEDLINE]
2.

Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.

Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.

Eur J Radiol. 2012 Jan;81(1):e19-25. doi: 10.1016/j.ejrad.2010.11.006. Epub 2010 Dec 3.

PMID:
21129871
[PubMed - indexed for MEDLINE]
3.

Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.

Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ.

J Nucl Med. 2007 Sep;48(9):1449-58. Epub 2007 Aug 17.

PMID:
17704250
[PubMed - indexed for MEDLINE]
Free Article
4.

Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.

Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A.

J Clin Oncol. 2006 Oct 1;24(28):4587-93.

PMID:
17008700
[PubMed - indexed for MEDLINE]
Free Article
5.

Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.

Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, Uematsu K, Sakai H, Goya T, Kanazawa M, Machida K.

Oncol Rep. 2012 Feb;27(2):333-8. doi: 10.3892/or.2011.1520. Epub 2011 Oct 24.

PMID:
22024889
[PubMed - indexed for MEDLINE]
6.

Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?

Sharif S, Zahid I, Routledge T, Scarci M.

Interact Cardiovasc Thorac Surg. 2011 May;12(5):806-11. doi: 10.1510/icvts.2010.255901. Epub 2011 Jan 25. Review.

PMID:
21266493
[PubMed - indexed for MEDLINE]
Free Article
7.

Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.

Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L.

J Thorac Oncol. 2010 Mar;5(3):385-8. doi: 10.1097/JTO.0b013e3181cbf465.

PMID:
20087231
[PubMed - indexed for MEDLINE]
8.

Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy.

Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL.

J Gastrointest Surg. 2007 Aug;11(8):961-9; discussion 969.

PMID:
17541799
[PubMed - indexed for MEDLINE]
9.

Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.

Kimura T, Koyama K, Kudoh S, Kawabe J, Yoshimura N, Mitsuoka S, Shiomi S, Hirata K.

Intern Med. 2008;47(23):2053-6. Epub 2008 Dec 1.

PMID:
19043260
[PubMed - indexed for MEDLINE]
Free Article
10.

A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.

Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ.

Clin Cancer Res. 2010 Apr 15;16(8):2409-17. doi: 10.1158/1078-0432.CCR-09-2313. Epub 2010 Apr 6.

PMID:
20371686
[PubMed - indexed for MEDLINE]
Free Article
11.

The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN.

Eur Radiol. 2009 Jun;19(6):1347-57. doi: 10.1007/s00330-009-1303-z. Epub 2009 Feb 13.

PMID:
19214522
[PubMed - indexed for MEDLINE]
12.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.

J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.

PMID:
18375898
[PubMed - indexed for MEDLINE]
Free Article
13.

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.

J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.

PMID:
18594323
[PubMed - indexed for MEDLINE]
14.

Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.

Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, Mitchell P, Knight SR, Feigen M, Scott AM.

Mol Imaging Biol. 2009 Nov-Dec;11(6):473-9. doi: 10.1007/s11307-009-0203-6. Epub 2009 Mar 28.

PMID:
19330385
[PubMed - indexed for MEDLINE]
15.

Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.

Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, Soyka JD, Veit-Haibach P, Seifert B, Kalff V.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1786-95. doi: 10.1007/s00259-008-0806-1. Epub 2008 May 6.

PMID:
18458901
[PubMed - indexed for MEDLINE]
16.

Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.

de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ.

J Nucl Med. 2007 Oct;48(10):1592-8. Epub 2007 Sep 14.

PMID:
17873138
[PubMed - indexed for MEDLINE]
Free Article
17.

18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.

Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, Zannini P.

Eur J Cardiothorac Surg. 2000 Apr;17(4):377-83.

PMID:
10773558
[PubMed - indexed for MEDLINE]
18.

Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A.

Mol Imaging Biol. 2009 Sep-Oct;11(5):369-78. doi: 10.1007/s11307-009-0212-5. Epub 2009 May 27.

PMID:
19472014
[PubMed - indexed for MEDLINE]
19.

Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.

Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, Gava M, Fanti S, Mariani G, Muzzio PC, Rubello D.

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1583-93. Epub 2007 May 15.

PMID:
17503039
[PubMed - indexed for MEDLINE]
20.

Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.

Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA.

Radiother Oncol. 2008 Dec;89(3):278-86. doi: 10.1016/j.radonc.2008.06.014. Epub 2008 Aug 11.

PMID:
18701180
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk